Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Quest Diagnostics Names Sukumar Nagendran, M.D., Vice President, Medical Affairs

Published: Thursday, April 04, 2013
Last Updated: Thursday, April 04, 2013
Bookmark and Share
In this role, Dr. Nagendran will provide medical oversight for the company's diagnostic information services.

He reports to Jon R. Cohen, M.D., senior vice president and chief medical officer, and will be based at the company's headquarters in Madison, NJ.

"Dr. Nagendran has an impressive record of successful medical affairs in several clinical areas as well as in new product and business development and clinical trial operations," said Dr. Cohen. "These experiences, combined with his relationships with top medical and healthcare experts, will help us to engage medical opinion leaders, payers and clients in more productive dialogues about the composition and value of our services. These competencies are critical as our company strives to be more externally focused and responsive to market needs."

Most recently, Dr. Nagendran served as vice president, head of medical affairs at Reata Pharma. Prior to that, he was therapeutic-area head for new product development, medical affairs, clinical operations and biometrics, in which he oversaw several therapeutic areas, including oncology, cardiovascular disease and diabetes, for Daiichi Sankyo. He has held other senior positions related to clinical development and medical affairs for Pfizer and Novartis.

Dr. Nagendran also has significant clinical practice experience. Early in his career, Dr. Nagendran practiced in a large internal-medicine physician group and was a staff physician at three hospitals in Phoenix, Arizona. In addition, he is formerly a member of the PrimeCare managed care committee for Phoenix-based Banner Health Systems, one of the largest nonprofit healthcare systems in the United States.

Dr. Nagendran's research on cardiovascular disease, diabetes, oncology, pulmonary medicine and other areas of medicine has been published in a number of peer-reviewed publications, including Endocrine Practice, Current Medical Research & Opinion and Journal of Clinical Lipidology.

Dr. Nagendran earned a bachelor's degree in biochemistry from Rutgers University and earned his doctorate in medicine from UMDNJ-Robert Wood Johnson Medical School in New Jersey, where he was given the Robert Wood Johnson Alumni award for outstanding medical student. He completed his internal medicine training at The Mayo Clinic in Rochester, Minn., and was inducted into the prestigious Mayo Alumni Laureate Group.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Quest Diagnostics Clinical Trials' Biorepository Accredited by the College of American Pathologists
Signifies achievement of highest quality standards for management of biological specimens and molecular material used in new drug development.
Wednesday, December 05, 2012
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!